DK1096924T3 - Inhibitorer af proteasomal aktivitet til stimulering af hårvækst - Google Patents

Inhibitorer af proteasomal aktivitet til stimulering af hårvækst

Info

Publication number
DK1096924T3
DK1096924T3 DK99933827T DK99933827T DK1096924T3 DK 1096924 T3 DK1096924 T3 DK 1096924T3 DK 99933827 T DK99933827 T DK 99933827T DK 99933827 T DK99933827 T DK 99933827T DK 1096924 T3 DK1096924 T3 DK 1096924T3
Authority
DK
Denmark
Prior art keywords
hair growth
inhibitors
stimulate hair
proteasomal activity
activity
Prior art date
Application number
DK99933827T
Other languages
English (en)
Inventor
Gregory R Mundy
I Ross Garrett
G Rossini
Original Assignee
Osteoscreen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osteoscreen Inc filed Critical Osteoscreen Inc
Application granted granted Critical
Publication of DK1096924T3 publication Critical patent/DK1096924T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • General Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
DK99933827T 1998-07-10 1999-07-09 Inhibitorer af proteasomal aktivitet til stimulering af hårvækst DK1096924T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/113,947 US6462019B1 (en) 1998-07-10 1998-07-10 Inhibitors of proteasomal activity and production for stimulating bone growth
PCT/US1999/015533 WO2000002548A2 (en) 1998-07-10 1999-07-09 Inhibitors of proteasomal activity for stimulating bone and hair growth

Publications (1)

Publication Number Publication Date
DK1096924T3 true DK1096924T3 (da) 2007-03-26

Family

ID=22352464

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99933827T DK1096924T3 (da) 1998-07-10 1999-07-09 Inhibitorer af proteasomal aktivitet til stimulering af hårvækst

Country Status (12)

Country Link
US (3) US6462019B1 (da)
EP (1) EP1096924B1 (da)
JP (2) JP2003522107A (da)
AT (1) ATE345785T1 (da)
AU (1) AU771297B2 (da)
CA (1) CA2337988C (da)
CY (1) CY1107323T1 (da)
DE (1) DE69934120T2 (da)
DK (1) DK1096924T3 (da)
ES (1) ES2273505T3 (da)
PT (1) PT1096924E (da)
WO (1) WO2000002548A2 (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US7052856B2 (en) * 1999-10-05 2006-05-30 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US7687462B2 (en) * 1999-10-05 2010-03-30 The Regents Of The University Of California Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition
WO2004024893A2 (en) * 2002-09-13 2004-03-25 The Regents Of The University Of California Nell-1 enhanced bone mineralization
US20090060988A1 (en) * 1999-10-05 2009-03-05 Kang Ting Nell-1 enhanced bone mineralization
US7544486B2 (en) * 2003-02-07 2009-06-09 The Regents Of The University Of California Nell peptide expression systems and bone formation activity of nell peptide
US7884066B2 (en) 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
EP1477180A1 (en) * 1999-10-20 2004-11-17 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
WO2004103410A1 (en) * 2002-06-06 2004-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
US7041309B2 (en) * 2002-06-13 2006-05-09 Neuropro Technologies, Inc. Spinal fusion using an HMG-CoA reductase inhibitor
WO2004009023A2 (en) * 2002-07-18 2004-01-29 University Of Utah Research Foundation Novel inhibitors of ubiquitin isopeptidases
US7029006B2 (en) * 2002-08-29 2006-04-18 Canon Kabushiki Kaisha Sheet feeding apparatus and image forming apparatus
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
WO2005046584A2 (en) * 2003-11-05 2005-05-26 Osteoscreen, Inc. Stimulation of hair growth by ginkgo biloba flavanoids
US7691607B2 (en) * 2004-02-09 2010-04-06 The Regents Of The University Of California Expression system of NELL peptide
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
JP5616569B2 (ja) 2004-04-15 2014-10-29 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 酵素阻害のための化合物
US7232818B2 (en) * 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
BRPI0510802A (pt) 2004-05-10 2007-11-06 Proteolix Inc compostos para inibição de enzima
US20050256324A1 (en) * 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
FR2870739B1 (fr) * 2004-05-26 2008-05-16 Oreal Utilisation du lif en cosmetique et en dermatologie
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
KR20070121669A (ko) 2005-02-16 2007-12-27 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 뼈 상태 치료 또는 예방을 위한 약제학적 조성물
JP5436860B2 (ja) * 2005-11-09 2014-03-05 オニキス セラピューティクス， インク． 酵素阻害のための化合物
NZ573759A (en) 2006-06-19 2012-03-30 Proteolix Inc Peptide epoxyketones for proteasome inhibition
WO2008099906A1 (ja) * 2007-02-16 2008-08-21 Anges Mg, Inc. 歯周病、及び外科手術による歯槽骨欠損の治療剤
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
EA018973B1 (ru) 2007-10-04 2013-12-30 Оникс Терапьютикс, Инк. Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
WO2011087822A1 (en) 2009-12-22 2011-07-21 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
PH12012501719A1 (en) 2010-03-01 2012-11-12 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
US8697646B2 (en) 2010-04-07 2014-04-15 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
CA2798517C (en) 2010-05-17 2016-07-05 The Procter & Gamble Company Systems and methods of detecting and demonstrating hair damage via evaluation of protein fragments
JP5737756B2 (ja) * 2011-07-06 2015-06-17 Ｎｅｃプラットフォームズ株式会社 通信装置およびパケット廃棄軽減方法
WO2013167927A1 (en) * 2012-05-11 2013-11-14 Biologix Hair Science Ltd. Formulation and method for treating hair loss
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
JP2015524411A (ja) * 2012-07-18 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． エポキシケトン系プロテアソーム阻害剤のリポソーム組成物
SG11201507629XA (en) * 2013-03-15 2015-10-29 Human Biomolecular Res Inst Compounds and matrices for use in bone growth and repair
CN111514128A (zh) * 2020-04-30 2020-08-11 广州中医药大学第一附属医院 羟基红花黄色素a在制备治疗骨质疏松药物中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761471A (en) 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
JPS60243008A (ja) * 1984-05-17 1985-12-03 Wakamoto Pharmaceut Co Ltd 発毛養毛剤
JPS6219513A (ja) * 1985-07-17 1987-01-28 Shiseido Co Ltd 養毛剤
ES2113857T3 (es) 1989-03-28 1998-05-16 Genetics Inst Composiciones osteoinductoras.
ES2074724T3 (es) 1990-08-14 1995-09-16 Howmedica Estimulador del crecimiento oseo.
JPH0597697A (ja) 1991-10-02 1993-04-20 Lion Corp 歯槽骨再生剤
WO1993020859A1 (en) 1992-04-20 1993-10-28 Board Of Regents Of The University Of Washington Sustained release compositions for delivery of growth factors
JPH08500482A (ja) * 1992-06-12 1996-01-23 マサチューセッツ インスティテュート オブ テクノロジー Ｃｅｄ−３及び関連蛋白質のインヒビター
US5962301A (en) * 1992-06-12 1999-10-05 Massachusetts Institute Of Technology Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5814605A (en) 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
US5840277A (en) 1993-03-30 1998-11-24 Charlotte Hospital Authority Treatment of chronic pulmonary inflammation
NZ275293A (en) 1993-10-21 1998-02-26 Merck & Co Inc 16-substituted-4-aza-androstanes for use as 5-alpha-reductase isozyme 1 inhibitors
US5580854A (en) 1994-03-04 1996-12-03 Mount Sinai School Of Medicine Of The City University Of New York Substrate-related peptidyl-aldehyde inhibitors of the proteolytic activity of the multicatalytic proteinase complex
DE69533176T2 (de) 1994-03-08 2005-09-15 Osteosa Liquidation Trust, San Diego Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
JPH11504209A (ja) * 1995-04-21 1999-04-20 メルク エンド カンパニー インコーポレーテッド アポパイン
US5767152A (en) 1995-05-04 1998-06-16 Nielsen; Thor Bagger Composition and methods for stimulating hair growth
US6083690A (en) 1995-06-02 2000-07-04 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents
US5728844A (en) 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
EP0850228A1 (en) 1995-09-01 1998-07-01 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
CA2235481A1 (en) 1995-10-23 1997-05-01 Sean M. Kerwin Compositions and methods for treating bone deficit conditions
FR2741076B1 (fr) * 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques derives des hormones thymiques, leur utilisation a titre de medicament et compositions les contenant
WO1997048694A1 (en) 1996-06-20 1997-12-24 Board Of Regents, The University Of Texas System Compounds and methods for providing pharmacologically active preparations and uses thereof
AU4988997A (en) 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
JP4269015B2 (ja) 1996-12-13 2009-05-27 オステオスクリーン アイピー， エルエルシー 骨の成長を刺激する組成物および方法
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
DE19716713A1 (de) 1997-04-21 1998-10-22 Paz Arzneimittelentwicklung Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
JPH11180873A (ja) 1997-12-22 1999-07-06 Kaken Shoyaku Kk ＮＦ−κＢ活性阻害剤
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6492333B1 (en) * 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors

Also Published As

Publication number Publication date
JP2006089498A (ja) 2006-04-06
EP1096924B1 (en) 2006-11-22
HK1035870A1 (en) 2001-12-14
CY1107323T1 (el) 2012-11-21
PT1096924E (pt) 2007-02-28
CA2337988C (en) 2011-04-26
CA2337988A1 (en) 2000-01-20
EP1096924A1 (en) 2001-05-09
ES2273505T3 (es) 2007-05-01
US6410512B1 (en) 2002-06-25
JP4469780B2 (ja) 2010-05-26
ATE345785T1 (de) 2006-12-15
JP2003522107A (ja) 2003-07-22
AU6310999A (en) 2000-02-01
US6958220B2 (en) 2005-10-25
WO2000002548A3 (en) 2003-04-17
AU771297B2 (en) 2004-03-18
DE69934120D1 (de) 2007-01-04
DE69934120T2 (de) 2007-10-11
WO2000002548A2 (en) 2000-01-20
US20020103127A1 (en) 2002-08-01
US6462019B1 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
ATE345785T1 (de) Inhibitoren der proteasomalen aktivität zur stimulierung des haarwuchses
PT1399220E (pt) Dispositivo que estimula a actividade dos folículos de cabelo
DE50107180D1 (de) Haartonikum zur Vorbeugung oder Behandlung von Haarausfall
EP1021179A4 (en) METHOD FOR PROMOTING HAIR GROWTH AND DEVELOPING THE HAIR SYSTEM
DE50015700D1 (de) Substituierte indole zur modulierung von nfkb-aktivität
ATE398464T1 (de) Synergie zwischen apo-2 ligand und antikörper gegen her-2
ATE236921T1 (de) L-ribavirin und dessen verwendung
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE3280344D1 (de) Verwendung von retinoiden und minoxidil (2,4-diamino-6-piperidino-pyrimidine-3-oxid) zur verbesserung des wachstums von menschlichem kopfhaar und zur behandlung bestimmter typen von alopecia.
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
ES2162647T3 (es) Composicion y procedimiento cosmetico para el tratamiento de perdida de cabello.
ATE308610T1 (de) Dreidimensionales hautmodell
DE60015516D1 (de) Verwendung von makroliden zur behandlung von trockenen augen
WO2001028579A3 (en) Inhibitors of proteasomal activity for stimulating bone and hair growth
ATE217514T1 (de) Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
ATE514771T1 (de) Haartransplantation
ATE275919T1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
ATE401078T1 (de) Die verwendung von c-kithemmern zur förderung des haarwuchses
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
TW200509957A (en) Stimulation of hair growth by compositions containing peptide copper complexes and minoxidil
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
EP1234574A4 (en) HAIR GROWTH FUNDS
DK1115375T3 (da) Anvendelse af mindst ét 10-hydroxy-2-decensyrederivat i et præparat til at fremme hudafstödning